These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16093813)

  • 1. Effect of anticoagulant drugs in cancer.
    Falanga A; Piccioli A
    Curr Opin Pulm Med; 2005 Sep; 11(5):403-7. PubMed ID: 16093813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?
    García-Escobar I; Beato-Zambrano C; Muñoz Langa J; Brozos Vázquez E; Obispo Portero B; Gutiérrez-Abad D; Muñoz Martín AJ;
    Clin Transl Oncol; 2018 Sep; 20(9):1097-1108. PubMed ID: 29470777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin in tumor progression and metastatic dissemination.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2007 Oct; 33(7):688-94. PubMed ID: 18000796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anticoagulant agents: introduction.
    Schulman S
    J Intern Med; 2003 Oct; 254(4):308-12. PubMed ID: 12974869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulants and cancer survival.
    Piccioli A; Falanga A; Prandoni P
    Semin Thromb Hemost; 2006 Nov; 32(8):810-3. PubMed ID: 17171594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies with anticoagulants to improve survival in cancer patients.
    Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
    Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?].
    Scharf RE
    Dtsch Med Wochenschr; 2011 Nov; 136(47):2403. PubMed ID: 22094968
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues.
    Blann A
    Curr Vasc Pharmacol; 2016; 14(3):220-36. PubMed ID: 26059459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
    Pritchard ER; Murillo JR; Putney D; Hobaugh EC
    J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
    Walenga JM; Lyman GH
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Which antithrombotic agents should be prescribed in deep venous thrombosis of the limbs?].
    Fiessinger JN
    Presse Med; 1994 Mar; 23(11):509-10. PubMed ID: 8022737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological and clinical aspects of anticancer effects of antithrombotics.
    Falanga A
    Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):389-92. PubMed ID: 15692249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin K antagonists in anticoagulant therapy of patients with cancer.
    Pasierski T
    Pol Arch Med Wewn; 2012; 122(1-2):60-4. PubMed ID: 22353708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices.
    Lee AY
    Dis Mon; 2005; 51(2-3):150-7. PubMed ID: 15900267
    [No Abstract]   [Full Text] [Related]  

  • 16. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins].
    Delsart D; Chambefort V; Decousus H
    Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082
    [No Abstract]   [Full Text] [Related]  

  • 17. The complex effects of heparins on cancer progression and metastasis in experimental studies.
    Smorenburg SM; Van Noorden CJ
    Pharmacol Rev; 2001 Mar; 53(1):93-105. PubMed ID: 11171940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Sailing in troubled waters': a review of the use of anticoagulation in adult cancer patients with thrombocytopenia.
    Ibrahim RB; Skewes MD; Kuriakose P
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):615-30. PubMed ID: 26945262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimetastatic activities of heparins and modified heparins. Experimental evidence.
    Borsig L
    Thromb Res; 2010 Apr; 125 Suppl 2():S66-71. PubMed ID: 20434009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.